反応式
C(O)(C(F)(F)F)=O.[CH:8]12[CH2:14][CH:11]([NH:12][CH2:13]1)[CH2:10][N:9]2[C:15]1[N:20]=[C:19]([NH2:21])[N:18]2[N:22]=[C:23]([C:25]3[O:26][CH:27]=[CH:28][CH:29]=3)[N:24]=[C:17]2[CH:16]=1.Cl[CH2:31][C:32]1[C:33]([CH3:38])=[N:34][O:35][C:36]=1[CH3:37].CCN(CC)CC>CC#N>[CH3:38][C:33]1[C:32]([CH2:31][N:12]2[CH2:13][CH:8]3[CH2:14][CH:11]2[CH2:10][N:9]3[C:15]2[N:20]=[C:19]([NH2:21])[N:18]3[N:22]=[C:23]([C:25]4[O:26][CH:27]=[CH:28][CH:29]=4)[N:24]=[C:17]3[CH:16]=2)=[C:36]([CH3:37])[O:35][N:34]=1参加物
6
実験手順
The TFA salt of 7-(2,5-diaza-bicyclo[2.2.1]hept-2-yl)-2-furan-2-yl-[1,2,4]triazolo[1,5-c]pyrimidin-5-ylamine (0.3 mmol; see Example 18 above) was dissolved in 3 mL of CH3CN along with 0.3 mmol of 4-chloromethyl-3,5-dimethyl-isoxazole (Aldrich-Sigma, St. Louis, Mo.) and 0.5 mmol of Et3N. The reaction mixture was stirred at room temperature for 18 hours. It was then concentrated and purified by preparative HPLC to afford the title compound. 1H NMR (400 Hz, DMSO-d6) δ 7.80 (d, J=1.0 Hz, 1H), 7.00 (d, J=3.6 Hz, 1H), 6.60 (dd, J=3.6, 1.0 Hz, 1H), 5.7 (s, 1H), 4.80 (brs, 2H), 2.4-3.6 (m, 14H). MS m/z: 407 [M+H]+.
後処理
- concentrationIt was then concentrated
- custompurified by preparative HPLC
出典と根拠
- ORDレコード
- ord-ff1540c77f164a4ebdad0305a39bbe0a
- 出典データセット
- uspto-grants-2010_11
- 特許番号
- US07834014B2
関連ノート
読み込み中…